With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback